THER SEC-arkivering - Theralink Technologies, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1362703

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Theralink Technologies, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 15, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-52218 THERALINK TECHNOLOGIES, INC. (Exact name of registrant as specified in
March 6, 2024	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 THERALINK TECHNOLOGIES, INC.
February 20, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralin
February 15, 2024	NT 10-Q	SEC FILE NUMBER SEC FILE NUMBER 000-52218 CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 15, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 ☐ TRANSITION RE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 The
January 5, 2024	EX-4.1	Description of Common Stock Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Theralink Technologies, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common stock, par value $0.0001 per share (the “Common Stock”) Description of Common Stock The following
January 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
January 5, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries None
December 29, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A200 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr
November 28, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 THERALINK TECHNOLOGIES, INC.
August 21, 2023	EX-4.1	Secured Convertible Promissory Note dated August 16, 2023 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITI
August 21, 2023	EX-10.1	Amended and Restated Security Agreement Exhibit 10.1 AMENDED AND RESTATED SECURITY AGREEMENT This AMENDED AND RESTATED SECURITY AGREEMENT, dated as of August 16, 2023 (this “Agreement”), is among Theralink Technologies, Inc., a Nevada corporation (the “Debtor” or the “Company”), the holders of the 10.0% Original Issue Discount Senior Secured Convertible Debentures issued by the Company (collectively, the “Debentures”) signatory hereto,
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Te
August 15, 2023	NT 10-Q	SEC FILE NUMBER SEC FILE NUMBER 000-52218 CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 THERALINK TECHNOLOGIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 THERALINK TECHNOLOGIES, INC.
June 29, 2023	EX-99.1	Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer Exhibit 99.1 Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces the appointm
May 26, 2023	EX-2.1	Agreement and Plan of Merger, dated as of May 23, 2023, by and among IMAC Holdings, Inc., IMAC Merger Sub, LLC and Theralink Technologies, Inc. Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among IMAC HOLDINGS, INC. IMAC MERGER SUB, INC. and THERALINK TECHNOLOGIES, INC. Dated as of May 23, 2023 TABLE OF CONTENTS ARTICLE I THE MERGER 5 Section 1.01 The Merger. 5 Section 1.02 Closing. 5 Section 1.03 Effective Time. 5 Section 1.04 Effects of the Merger. 5 Section 1.05 Certificate of Incorporation; By-Laws. 5 Section 1.06
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 THERALINK TECHNOLOGIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 THERALINK TECHNOLOGIES, INC.
May 26, 2023	EX-99.1	Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company Theralink’s patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict Exhibit 99.1 Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company Theralink’s patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict which FDA-approved drugs may be effective in each solid tumor cancer Golden, Colorado — May 23, 2023— Theralink Technologies, Inc. (OTC:
May 26, 2023	EX-99.1	Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company Theralink’s patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict Exhibit 99.1 Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company Theralink’s patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict which FDA-approved drugs may be effective in each solid tumor cancer Golden, Colorado — May 23, 2023— Theralink Technologies, Inc. (OTC:
May 26, 2023	EX-2.1	Agreement and Plan of Merger, dated as of May 23, 2023, by and among IMAC Holdings, Inc., IMAC Merger Sub, LLC and Theralink Technologies, Inc. Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among IMAC HOLDINGS, INC. IMAC MERGER SUB, INC. and THERALINK TECHNOLOGIES, INC. Dated as of May 23, 2023 TABLE OF CONTENTS ARTICLE I THE MERGER 5 Section 1.01 The Merger. 5 Section 1.02 Closing. 5 Section 1.03 Effective Time. 5 Section 1.04 Effects of the Merger. 5 Section 1.05 Certificate of Incorporation; By-Laws. 5 Section 1.06
May 26, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 THERALINK TECHNOLOGIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 THERALINK TECHNOLOGIES, INC.
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 THERALINK TECHNOLOGIES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 THERALINK TECHNOLOGIES, INC.
February 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technolog
February 15, 2023	NT 10-Q	SEC FILE NUMBER NT 10-Q 1 formnt10-q.htm ☒ SEC FILE NUMBER 000-52218 ☐ CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transit
February 1, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 THERALINK TECHNOLOGIES, INC.
December 29, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries None
December 29, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
December 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 THERALINK TECHNOLO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 THERALINK TECHNOLOGIES, INC.
December 9, 2022	EX-10.1	Offer Letter between the Company and Faith Zaslavsky, dated December 5, 2022 EXHIBIT 10.1 Faith Zaslavsky Dear Faith: I am delighted to confirm the verbal offer of employment by Theralink Technologies, Inc. (?Theralink? or the ?Company?) extended to you on October 19, 2022. Your position will be as President & COO reporting directly to the CEO, Mick Ruxin, M.D. in Golden, Colorado starting on December 5, 2022. Unless otherwise agreed to in writing, you shall render the ser
December 9, 2022	EX-99.1	Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company EXHIBIT 99.1 Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company GOLDEN, Colo., Dec. 6, 2022 /PRNewswire/ — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), the only US precision oncology company with commercial RPPA technology that can tell which FDA-approved drug is effective in
December 1, 2022	EX-4.3	Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Exchanged Debentures) Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
December 1, 2022	EX-4.2	Form of Common Stock Purchase Warrant Exhibit 4.2 EXHIBIT D NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
December 1, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 THERALINK TECHNOLOGIES, INC.
December 1, 2022	EX-10.1	Placement Agency Agreement by and between the Company and Joseph Gunnar & Co. Exhibit 10.1 JOSEPH GUNNAR & CO., LLC 30 Broad Street, 11th Floor New York, NY 10004 November 29, 2022 Theralink Technologies, Inc. 15000 W. 6th Ave., #400 Golden, CO 80401 Attn: Mick Ruxin, M.D. Dear Mr. Ruxin: This Placement Agency Agreement will confirm our agreement that Theralink Technologies, Inc. (the ?Company?) has engaged Joseph Gunnar & Co., LLC (?Gunnar? or ?Placement Agent?) to act as
December 1, 2022	EX-10.2	Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT EXHIBIT LIST A. Form of Legacy Holder Debenture B. Form of New Holder Debenture C. Form of Security Agreement D. Form of Warrant E. Form of Lock Up -Insiders F. Purchaser Questionnaire G. Term Sheet H. Form of Purchaser Leak-Out I. Form of Exchange Agreement J. Warrant Amendment 2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agr
December 1, 2022	EX-10.3	Form of Security Agreement Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of November 29, 2022 (this ?Agreement?), is among Theralink Technologies, Inc., a Nevada corporation (the ?Debtor? or the ?Company?), the holders of the 10.0% Original Issue Discount Senior Secured Convertible Debentures issued by the Company in the original aggregate principal amount of up to $[] (collectively, the ?Debentures?) si
December 1, 2022	EX-4.1	Form of 10% Original Issue Discount Senior Secured Convertible Debentures Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
December 1, 2022	EX-99.1	Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares Exhibit 99.1 Theralink? Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares Golden, Colorado ? November 29, 2022 ? Theralink Technologies, Inc. (OTC:THER) (?Theralink? or the ?Company?), a precision oncology company with a novel phosphoprotein-based assay for breast cancer, today announced that it has entered into defini
September 16, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 THERALINK TECHNOLOGIES, INC.
September 16, 2022	EX-10.1	Form of Demand Note Exhibit 10.1 DEMAND PROMISSORY NOTE FOR VALUE RECEIVED, Theralink Technologies, Inc., a Nevada corporation (?Borrower?), having an office at 15000 W. 6th Ave., Suite 400, Golden, Colorado 80401, unconditionally promises to pay to the order of [ ] (?Lender?), at his address at [ ] or at such other place as Lender may designate in writing, the principal sum of [ ] Thousand ($[ ],000) (the ?Loan?) ou
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
July 12, 2022	8-K/A	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
July 12, 2022	EX-3.1	Certificate of Amendment, as filed on July 1, 2022 Exhibit 3.1
July 7, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 THERALINK TECHNOLOGIES, INC.
July 7, 2022	EX-3.1	Certificate of Amendment as filed on July 1, 2022 Exhibit 3.1
June 2, 2022	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement THERALINK TECHNOLOGIES, INC. (Nam
May 23, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies
May 23, 2022	EX-4.1	Form of Convertible Promissory Note for April 2022 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITI
May 23, 2022	EX-4.2	Form of Common Stock Purchase Warrant for April 2022 Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
May 23, 2022	EX-10.1	Form of Securities Purchase Agreement for April 2022 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April [ ], 2022, between Theralink Technologies, Inc., a Nevada corporation (the ?Company?), and each investor identified on the signature pages to this Agreement (each a ?Purchaser?). WHEREAS, the Company is seeking to raise $3 million, which amount will be subject to increase upon the
May 20, 2022	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c?101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement THERALINK TECHNOLOGIES, INC. (Nam
May 17, 2022	NT 10-Q	SEC FILE NUMBER NT 10-Q 1 formnt10-q.htm SEC FILE NUMBER 000-52218 CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Rep
April 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 THERALINK TECHNOLOGIES, INC.
February 18, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technolog
February 15, 2022	NT 10-Q	SEC FILE NUMBER NT 10-Q 1 formnt10-q.htm ☒ ☐ SEC FILE NUMBER 000-52218 CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transit
February 3, 2022	EX-10.2	Engagement Letter, by and between Carter, Terry & Company and Theralink Technologies, Inc., dated December 15, 2021, as amended Exhibit 10.2 Carter, Terry & Company. 3060 Peachtree Rd, Suite 1200, Atlanta GA 30305 Phone: 404-364-3070-Member FINRA SIPC December 15, 2021 Mick Ruxin, M.D. Theralink Technologies, Inc 15000 West 6th Avenue Suite 400 Golden, CO 80401 Subject: Private Placement Offering for Theralink Technologies, Inc It is our understanding that Theralink Technologies, Inc, the ?Company?, desires to raise capita
February 3, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 THERALINK TECHNOLOGIES, INC.
February 3, 2022	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January , 2022, between Theralink Technologies, Inc., a Nevada corporation (the ?Company?), and each investor identified on the signature pages to this Agreement (each a ?Purchaser?). WHEREAS, the Company is seeking to raise a maximum of $3 million (the ?Maximum?) in an offering of Notes
February 3, 2022	EX-4.3	Form of Common Stock Purchase Warrant 2 Exhibit 4.3 136NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC
January 13, 2022	EX-10.6	Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk effective January 1, 2021* Exhibit 10.6
January 13, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries None
January 13, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
January 13, 2022	EX-3.1	Amended and Restated Articles of Incorporation, as amended Exhibit 3.1
January 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 THERALINK TECHNOLOGIES, INC.
December 30, 2021	NT 10-K	SEC FILE NUMBER ☒ ☐ SEC FILE NUMBER 000-52218 CUSIP NUMBER 68235A200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 29, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 THERALINK TECHNOLOGIES, INC.
November 5, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 THERALINK TECHNOLOGIES, INC.
November 5, 2021	EX-4.1	Form of Convertible Promissory Note Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITI
November 5, 2021	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 1, 2021, between Theralink Technologies, Inc., a Nevada corporation (the ?Company?), and each investor identified on the signature pages to this Agreement (each a ?Purchaser?). WHEREAS, the Company is seeking to raise a maximum of $3 million (the ?Maximum?) in an offering of Not
November 5, 2021	EX-4.2	Form of Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
September 28, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
September 27, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies,
September 27, 2021	EX-10.14	Employment Agreement, dated June 5, 2020 by and between Jeffrey Busch and OncBioMune Pharmaceuticals, Inc.* Exhibit 10.14 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made and entered into by and between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the ?Company?), and Jeffrey Busch (?Employee?) dated June 5, 2020. WHEREAS, the parties hereto desire to enter into this Agreement in order to secure the services of the Employee for the benefit of the Company,
September 27, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technologies
September 27, 2021	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Name of Subsidiaries Jurisdiction OncBioMune, Inc. Louisiana
September 27, 2021	EX-10.13	Employment Agreement, dated June 5, 2020 by and between Dr. Michael Ruxin and OncBioMune Pharmaceuticals, Inc.* Exhibit 10.13 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made and entered into by and between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the ?Company?), and Michael I. Ruxin, M.D. (?Employee?) dated June 5, 2020. WHEREAS, the parties hereto desire to enter into this Agreement in order to secure the services of the Employee for the benefit of the
September 27, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technolog
August 6, 2021	EX-4.1	Common Stock Purchase Warrant, dated July 30, 2021 Exhibit 4.1 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
August 6, 2021	EX-10.1	Securities Purchase Agreement, dated July 30, 2021 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 30, 2021, between Theralink Technologies, Inc., a Nevada corporation (the ?Company?), and each investor identified on the signature pages to this Agreement (each a ?Purchaser?). WHEREAS, the Company has authorized a new series of convertible preferred stock of the Company designated
August 6, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 THERALINK TECHNOLOGIES, INC.
August 6, 2021	EX-3.1	Designation for Series F Convertible Preferred Stock Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES F CONVERTIBLE PREFERRED STOCK OF THERALINK TECHNOLOGIES, INC. The undersigned, Mick Ruxin, M.D., President and Chief Executive Officer of Theralink Technologies, Inc. (the ?Corporation?), a corporation organized and existing under Chapter 78 of the Nevada Revised Statues (the ?NRS?), hereby does certify: That pursuant to
June 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52218 Theralink Technolog
June 11, 2021	EX-3.1	Amended and Restated Articles of Incorporation, as amended Exhibit 3.1
June 11, 2021	EX-3.3	Amendment to Certificate of Designation for Series C-1 Convertible Preferred Stock Exhibit 3.3
June 8, 2021	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 THERALINK TECHNOLOGIES, INC.
June 8, 2021	EX-16.1	Letter from Weinstein International C.P.A. dated June 8, 2021 Exhibit 16.1 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of the Form 8-K dated on or about June 8, 2021, of Theralink Technologies Inc. and are in agreement with the statements contained therein inasmuch as they relate to our firm. We have no basis to agree or disagree with other statements o
May 19, 2021	EX-4.1	Convertible Secured Promissory Note, dated May 12, 2021 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITI
May 19, 2021	EX-10.2	Security Agreement, dated May 12, 2021 Exhibit 10.2 SECURITY AGREEMENT This Security Agreement, dated as of May 12, 2021 (the ?Agreement?) is made by and among Theralink Technologies, Inc., a corporation duly organized and validly existing under the laws of Nevada (together with its Subsidiaries, the ?Company?), Ashton Capital Corporation and any other party who may sign a Secured Party signature page attached hereto (each, a ?Secured
May 19, 2021	EX-10.1	Securities Purchase Agreement, dated May 12, 2021 EX-10.1 4 ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2021, between Theralink Technologies, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages to this Agreement (each a “Purchaser”). WHEREAS, the Company is seeking to raise a maximum of $4 million (the “Maximum”) in a
May 19, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 THERALINK TECHNOLOGIES, INC.
May 19, 2021	EX-4.2	Common Stock Purchase Warrant, issued May 12, 2021 Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
April 20, 2021	EX-99.1	AVANT DIAGNOSTICS, INC. BALANCE SHEETS Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Avant Diagnostics, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Avant Diagnostics, Inc. (?the Company?) as of September 30, 2019 and 2018 and the related statements of operations, changes in stockholders? deficit and cash flows, for e
April 20, 2021	EX-10.2	Form of Registration Rights Agreement EX-10.2 3 ex10-2.htm Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”), is made and entered into as of March [], 2021, by and among Theralink Technologies, Inc., a Nevada corporation (the “Company”) and each undersigned shareholder set forth on the signature page hereto (the “Shareholder”, and all together with the Company, the “Parties” and each, a “
April 20, 2021	EX-10.1	Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is made by and between Theralink Technologies, Inc. a Nevada corporation (the ?Company?), and the undersigned (?Subscriber?) as of the date this Subscription Agreement is accepted by the Company, as set forth on the Company?s signature page hereto. WHEREAS, subject to the terms and conditions set forth
April 20, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 THERALINK TECHNOLOGIES, INC.
April 20, 2021	EX-99.2	AVANT DIAGNOSTICS, INC. CONDENSED BALANCE SHEETS EX-99.2 3 ex99-2.htm Exhibit 99.2 AVANT DIAGNOSTICS, INC. CONDENSED BALANCE SHEETS (UNAUDITED) March 31, September 30, 2020 2019 ASSETS CURRENT ASSETS: Cash $ 1,208,653 $ 560,407 Accounts receivable 17,454 4,000 Prepaid expenses and other current assets 150,858 9,054 Total Current Assets 1,376,965 573,461 OTHER ASSETS: Property and equipment, net 670,119 298,910 Finance right-of-use asset, net 181
April 20, 2021	8-K/A	Financial Statements and Exhibits 8-K/A 1 form8-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 THERALINK TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jur
April 20, 2021	EX-99.3	UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined balance sheet is based on the historical consolidated balance sheet of OncBioMune Pharmaceuticals, Inc. and Subsidiaries (?OBMP? or ?Company?) and Avant Diagnostics, Inc. (?Avant?) at March 31, 2020 after giving effect to; (1) the Asset Purchase Agreement dated May 12, 2020 between the Compan
April 20, 2021	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 THERALINK TECHNOLOGIES, INC.
October 29, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 THERALINK TECHNOLOGIES, INC.
October 29, 2020	EX-99.1	Investor Presentation Exhibit 99.1
September 29, 2020	EX-99.1	Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer EX-99.1 2 ex99-1.htm Exhibit 99.1 Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced the appointment of Thomas E. Chilcott, III CPA
September 29, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 THERALINK TECHNOLOGIES, INC.
September 22, 2020	EX-10.1	Securities Purchase Agreement, dated September 16, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investor Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 16, 2020, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Doug Mergenthaler (the “Purchaser”). WHEREAS, the Company has authorized a new series of convertible preferred stock of the Company designated as Series E Convertible Preferred Stock (
September 22, 2020	EX-3.1	Designation for Series E Convertible Preferred Stock EX-3.1 2 ex3-1.htm Exhibit 3.1
September 22, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
August 31, 2020	DEFM14C	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [X] Definitive Information Statement ONCBIOMUNE PHARMACEUTICALS, I
August 26, 2020	EX-99.1	Investor Presentation Exhibit 99.1
August 26, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
August 19, 2020	EX-99.3	UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined balance sheet is based on the historical consolidated balance sheet of OncBioMune Pharmaceuticals, Inc. and Subsidiaries (“OBMP” or “Company”) and Avant Diagnostics, Inc. (“Avant”) at March 31, 2020 after giving effect to; (1) the Asset Purchase Agreement dated May 12, 2020 between the Compan
August 19, 2020	EX-99.1	AVANT DIAGNOSTICS, INC. CONSOLIDATED BALANCE SHEETS FOR THE YEARS ENDED SEPTEMBER 30, 2019 AND 2018 EX-99.1 2 ex99-1.htm Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Avant Diagnostics, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Avant Diagnostics, Inc. (“the Company”) as of September 30, 2019 and 2018 and the related statements of operations, changes in stockholders’ deficit
August 19, 2020	8-K/A	Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
August 19, 2020	PREM14C	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [ ] Definitive Information Statement ONCBIOMUNE PHARMACEUTICALS, I
August 19, 2020	EX-99.2	AVANT DIAGNOSTICS, INC CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.2 AVANT DIAGNOSTICS, INC CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2020 September 30, 2019 (Unaudited) ASSETS Current Assets: Cash $ 1,207,898 $ 569,960 Accounts receivable 17,454 - Prepaid expenses 98,907 - Total current assets 1,324,258 569,960 Other Assets: Intellectual Property 3,075,868 3,209,602 Website development cost, net 1,596 2,125 Patent costs, net 160,500 124,668 Furn
August 18, 2020	NT 10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on
July 22, 2020	CORRESP	- CORRESP 1 filename1.htm OncBioMune Pharmaceuticals, Inc. 8000 Innovation Park Dr. Baton Rouge, LA 70820 July 22, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, DC 20549 Attention: Tracey McKoy Jeanne Baker Terence O’Brien Re: OncBioMune Pharmaceuticals, Inc. Form 8-K for the period ended June 5
June 15, 2020	SC 13D	OBMP / OncBioMune Pharmaceuticals, Inc. / Avant Diagnostics, Inc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ONCBIOMUNE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68235A200 (CUSIP Number) Michael Ruxin, M.D. Chief Executive Officer Avant Diagnostics, Inc. 15000 W. 6th Ave., Suite 400 Golden, CO 80401 (Name, Addr
June 11, 2020	EX-99.2	OncBioMune Appoints Dr. Mick Ruxin as President & CEO and Jeffrey Busch as Chairman of the Board Exhibit 99.2 OncBioMune Appoints Dr. Mick Ruxin as President & CEO and Jeffrey Busch as Chairman of the Board Golden, Colorado - June 10, 2020 - OncBioMune Pharmaceuticals, Inc. (OTC: OBMP) (“OncBioMune”) today announced the appointment of Mick Ruxin, M.D. as President & CEO and Mr. Jeffrey Busch as Chairman of the Board upon closing of its previously announced asset purchase agreement (Link: http
June 11, 2020	EX-10.2	Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein Exhibit 10.2 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and such persons listed on Schedule I who have executed a signature page to this Agreement (each, an “Investor”). WHEREAS, the Investor has previously acquired various securities from the Company in
June 11, 2020	EX-3.5	Certificate of Withdrawal of Certificate of Designation EX-3.5 6 ex3-5.htm Exhibit 3.5
June 11, 2020	EX-3.3	Certificate of Designation for Series D-2 Convertible Preferred Stock Exhibit 3.3 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES D-2 CONVERTIBLE PREFERRED STOCK OF ONCBIOMUNE PHARMACEUTICALS, INC. The undersigned, Andrew Kucharchuk, President and Chief Executive Officer of OncBioMune Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under Chapter 78 of the Nevada Revised Statues (the “NRS”), hereby does certify: That
June 11, 2020	EX-10.4	Securities Purchase Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc., Cavalry Fund I LP and Lincoln Park Capital Fund, LLC Exhibit 10.4 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is effective as of the 5th day of June 2020 (the “Closing Date”), by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages to this Agreement (each, an “Investor”). WHEREAS, subject to the terms and conditions set forth in
June 11, 2020	EX-10.6	Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020 Exhibit 10.6 Consulting Agreement This consulting agreement (the “Agreement”), effective 5th day of June, 2020 (“Effective Date”) by and between Andrew Kucharchuk (“Consultant”), an individual whose address is 549 Millgate Place, Baton Rouge, LA 70808 and OncBioMune Pharmaceuticals, Inc., a Nevada corporation with its principal office located at 8000 Innovation Park Dr., Baton Rouge, LA 70820 toge
June 11, 2020	EX-3.4	Certificate of Designations of the Series D-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the Current Report on Form 8-K filed by OncBioMune Pharmaceuticals, Inc. on June 11, 2020). EX-3.4 5 ex3-4.htm Exhibit 3.4 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES D-1 CONVERTIBLE PREFERRED STOCK OF ONCBIOMUNE PHARMACEUTICALS, INC. The undersigned, Andrew Kucharchuk, President and Chief Executive Officer of OncBioMune Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under Chapter 78 of the Nevada Revised Statues (the “NRS”), hereby
June 11, 2020	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
June 11, 2020	EX-3.1	Certificate of Designation for Series C-1 Convertible Preferred Stock Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C-1 CONVERTIBLE PREFERRED STOCK OF ONCBIOMUNE PHARMACEUTICALS, INC. The undersigned, Andrew Kucharchuk, President and Chief Executive Officer of OncBioMune Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under Chapter 78 of the Nevada Revised Statues (the “NRS”), hereby does certify: That
June 11, 2020	EX-4.1	Form of Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED (THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT O
June 11, 2020	EX-4.2	Exchange Warrant, dated June 5, 2020 Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
June 11, 2020	EX-3.2	Certificate of Designation for Series C-2 Convertible Preferred Stock Exhibit 3.2 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C-2 CONVERTIBLE PREFERRED STOCK OF ONCBIOMUNE PHARMACEUTICALS, INC. The undersigned, Andrew Kucharchuk, President and Chief Executive Officer of OncBioMune Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under Chapter 78 of the Nevada Revised Statues (the “NRS”), hereby does certify: That
June 11, 2020	EX-10.3	Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, PhD Exhibit 10.3 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Jonathan F. Head, Ph.D., a natural person residing in Louisiana (the “Holder”). WHEREAS, the Holder has previously acquired 667 shares of Series A Preferred Stock of the Company and 3,856 shares
June 11, 2020	EX-99.1	OncBioMune Announces Closing of Asset Purchase Agreement with Avant Diagnostics Avant Diagnostics provides personalized medicine data for physicians and measures the activation state of key drug targets and signaling pathways for Biopharmas through i Exhibit 99.1 OncBioMune Announces Closing of Asset Purchase Agreement with Avant Diagnostics Avant Diagnostics provides personalized medicine data for physicians and measures the activation state of key drug targets and signaling pathways for Biopharmas through its Theralink® assays The stock will continue to be listed on OTC markets under the symbol “OBMP” Golden, Colorado - June 8, 2020 - OncBio
June 11, 2020	EX-10.1	Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 5th day of June 2020, by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and such persons listed on Schedule I who have executed a signature page to this Agreement (each, an “Investor”). WHEREAS, the Investor has previously acquired various securities from the Company in
June 11, 2020	EX-10.5	Separation Agreement and General Release of Claims between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk, dated June 5, 2020 Exhibit 10.5 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Separation Agreement and General Release of Claims (“Agreement”) is entered into by Andrew Kucharchuk (hereinafter referred to as “you” or “your”) and OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”). In consideration of the mutual promises set forth below, the parties agree as follows: 1. Separation of Empl
June 8, 2020	SC 14F1	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 Information Statement Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 Thereunder Commission file number 000-52218 ONCBIOMUNE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 20-2590810 (State or Other Jurisdiction of Incorporation or Organization
June 1, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
May 15, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIO
May 13, 2020	8-K	Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
May 13, 2020	EX-2.1	Asset Purchase Agreement, dated May 12, 2020, by and among OncBioMune Pharmaceuticals, Inc. and Avant Diagnostics, Inc. Exhibit 2.1 ASSET PURCHASE AGREEMENT between AVANT DIAGNOSTICS, INC. and ONCBIOMUNE PHARMACEUTICALS, INC. dated as of May 12, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE 9 Section 2.01 Purchase and Sale of Assets 9 Section 2.02 Assumed Liabilities 10 Section 2.03 Excluded Liabilities 10 Section 2.04 Consideration 11 Section 2.05 Tax Treatment of Consideration 1
May 8, 2020	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 ONCBIOMUNE PHARMACEUTICALS, INC.
March 25, 2020	EX-4.1	Description of Common Stock Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OncBioMune Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common stock, par value $0.0001 per share (the “Common Stock”) Description of Common Stock The follow
March 25, 2020	10-K	OBMP / OncBioMune Pharmaceuticals, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-52218 (Commission File Number) OncBioMu
March 25, 2020	EX-3.1	Amended and Restated Articles of Incorporation, as amended
March 25, 2020	EX-21.1	Subsidiaries of OncBioMune Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries Name of Subsidiaries Jurisdiction OncBioMune, Inc. Louisiana
November 19, 2019	EX-4.1	Note dated September 25, 2019 EX-4.1 2 ex4-1.htm execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
November 19, 2019	EX-10.1	Securities Purchase Agreement dated September 25, 2019 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2019, between OncBioMune Pharmaceuticals, Inc.
November 19, 2019	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ON
November 19, 2019	EX-4.2	Warrant dated September 25, 2019 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM
November 15, 2019	NT 10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo
September 13, 2019	EX-3.1	Certificate of Change of OncBioMune Pharmaceuticals, Inc., dated August 28, 2019.
September 13, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2019 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (C
August 15, 2019	NT 10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on
August 15, 2019	10-Q	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002. Exhibit 31.1 CERTIFICATIONS I, Brian Barnett, MD, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2019 of OncBioMune Pharmaceuticals, Inc. (the “registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
August 6, 2019	EX-4.2	Form of Warrant execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
August 6, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2019 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Commis
August 6, 2019	EX-4.1	Form of Note EX-4.1 2 ex4-1.htm execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
August 6, 2019	EX-10.1	Form of Securities Purchase Agreement dated June 3, 2019 (incorporated by reference to Exhibit 10.1 to registrant’s current report on Form 8-K filed with the SEC on August 6, 2019). Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between OncBioMune Pharmaceuticals, Inc.
July 18, 2019	EX-4.1	Form of Note execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
July 18, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2019 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction (Commission (IRS Employe
July 18, 2019	EX-10.1	Form of Common Stock Purchase Warrant execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2019, between OncBioMune Pharmaceuticals, Inc.
July 18, 2019	EX-4.2	Form of Securities Purchase Agreement between OncBioMune Pharmaceuticals, Inc. execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
May 15, 2019	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIO
May 13, 2019	DEF 14C	OBMP / OncBioMune Pharmaceuticals, Inc. DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [X] Definitive Information Statement ONCBIOMUNE PHARMACEUTICALS
May 2, 2019	EX-10.1	Form of Securities Purchase Agreement EX-10.1 4 ex10-1.htm Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2019, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, su
May 2, 2019	EX-4.2	Form of Warrant issued April 29, 2019 (incorporated by reference to Exhibit 4.2 to registrant’s current report on Form 8-K filed with the SEC on May 2, 2019). execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
May 2, 2019	EX-4.1	Form of Note issued April 29, 2019 (incorporated by reference to Exhibit 4.1 to registrant’s current report on Form 8-K filed with the SEC on May 2, 2019). execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
May 2, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2019 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction (Commission (IRS Employ
April 30, 2019	PRE 14C	OBMP / OncBioMune Pharmaceuticals, Inc. PRE 14C PRE 14C 1 pre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [ ] Definitive Information Statement ONCBI
April 1, 2019	EX-10.46	Common Stock Purchase Warrant issued March 25, 2019 to Cavalry Fund I LP Exhibit 10.46 execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
April 1, 2019	EX-21.1	Subsidiaries of OncBioMune Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries Name of Subsidiaries Jurisdiction OncBioMune, Inc. Louisiana
April 1, 2019	10-K	OBMP / OncBioMune Pharmaceuticals, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-52218 (Commission File Number) OncBioMu
April 1, 2019	EX-10.45	Securities Purchase Agreement between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP, dated March 25, 2019 Exhibit 10.45 execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 25, 2019, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Cavalry Fund I LP (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirement
April 1, 2019	EX-10.44	Senior Convertible Note issued March 25, 2019 to Cavalry Fund I LP Exhibit 10.44 execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
April 1, 2019	EX-10.39	Employment Agreement effective as of December 26, 2018 between OncBioMune Pharmaceuticals, Inc. and Brian Barnett, MD Exhibit 10.39 EMPLOYMENT AGREMENT BETWEEN: Brian Barnett, MD (the “Executive”), an individual with his main address at: 230 N Springer Rd Los Altos, CA 94024 AND: OncBioMune Pharmaceuticals, Inc. (the “Company”), an entity organized and existing under the laws of the State of Nevada, with its head office located at: 11441 Industriplex Blvd Suite 190 Baton Rouge, LA 70809 Recitals In consideration
March 19, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2019 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Comm
March 19, 2019	EX-99.1	Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment BATON ROUGE, La.
March 6, 2019	DEF 14C	OBMP / OncBioMune Pharmaceuticals, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [X] Definitive Information Statement ONCBIOMUNE PHARMACEUTICALS
February 22, 2019	PRE 14C	OBMP / OncBioMune Pharmaceuticals, Inc. PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c−101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2)) [ ] Definitive Information Statement ONCBIOMUNE PHARMACEUTICALS
February 21, 2019	EX-10.2	Irrevocable Trust Agreement Number F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. as beneficiaries and Banco Actinver, S.A., as Trustee (“Banco Actinver”) (the “Trust Agreement”) dated March 10, 2017. IRREVOCABLE MANAGEMENT TRUST AGREEMENT NUMBER F/2868 (TWO THOUSAND EIGHT HUNDRED SIXTY EIGHT) DATED March 10, 2017 (THE “AGREEMENT”), ENTERED INTO BY AND BETWEEN EACH OF MANUEL COSME ODABACHIAN AND CARLOS FERNANDO ALAMAN VOLNIE, IN THEIR CAPACITY AS TRUSTORS AND BENEFICIARIES (COLLECTIVELY, “BENEFICIARY A”), ON THEIR OWN BEHALF; ONCBIOMUNE PHARMACEUTICALS, INC.
February 21, 2019	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Com
February 21, 2019	EX-10.3	Shareholders Agreement among OncBioMune Pharmaceuticals, Inc., Jonathan F. Head, Ph.D., Andrew A. Kucharchuk, Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March 10, 2017. Execution Version STOCKHOLDERS’ AGREEMENT dated as of March 10, 2017 among ONCBIOMUNE PHARMACEUTICALS, INC.
February 21, 2019	EX-10.1	Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March 10, 2017. Execution Version CONTRIBUTION AGREEMENT TO THE PROPERTY OF TRUST F/2868 (TWO THOUSAND EIGHT HUNDRED SIXTY EIGHT) (THIS “AGREEMENT”), dated March 10, 2017, pursuant to the following recitals, representations and clauses, by and between each of: PARTIES I.
February 4, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2018 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Co
February 4, 2019	EX-10.1	Securities Purchase Agreement dated January 18, 2019 between OncBioMune Pharmaceuticals, Inc. and Cerberus Finance Group Ltd SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc.
February 4, 2019	EX-4.1	Convertible Redeemable Note issued January 18, 2019 to Cerberus Finance Group Ltd THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $88,125.
January 28, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2018 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Co
January 28, 2019	EX-4.1	Convertible Redeemable Note issued January 18, 2019 to LG Capital Funding, LLC Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $146,87
January 28, 2019	EX-10.1	Securities Purchase Agreement dated January 18, 2019 between OncBioMune Pharmaceuticals, Inc. and LG Capital Funding, LLC EX-10.1 3 ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc., a Nevada corporation, with headquarters located at 11441 Industriplex Blvd., Suite 190, Baton Rouge, LA 70809 (the “Company”), and LG CAPITAL FUNDING, LLC, a New York limited liability company, with its
December 27, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 26, 2018 OncBioMune Pharmaceuticals, Inc.
November 14, 2018	EX-10.12	Common Stock Purchase Warrant issued November 13, 2018 to Cavalry Fund I LP EX-10.12 11 ex10-12.htm Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
November 14, 2018	EX-10.6	Escrow Agreement dated September 24, 2018 by and among OncBioMune Pharmaceuticals, Inc., Nason, Yeager, Gerson, White & Lioce, P.A., and the parties who later execute such agreement Execution Copy ESCROW AGREEMENT This Escrow Agreement (the “Agreement”) is entered into as of September 24, 2018 by and among OncBioMune Pharmaceuticals, Inc.
November 14, 2018	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ON
November 14, 2018	EX-10.3	Securities Purchase Agreement dated September 24, 2018 between OncBioMune Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto EX-10.3 2 ex10-3.htm execution copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2018, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, s
November 14, 2018	EX-10.10	Securities Purchase Agreement dated November 13, 2018 between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP EX-10.10 9 ex10-10.htm execution copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 13, 2018, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Cavalry Fund I LP (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration
November 14, 2018	EX-10.9	Form of Common Stock Purchase Warrant issued September 24, 2018 EX-10.9 8 ex10-9.htm Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
November 14, 2018	EX-10.5	Pledge Agreement dated September 24, 2018 between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP EX-10.5 4 ex10-5.htm Execution Copy PLEDGE AGREEMENT THIS PLEDGE AGREEMENT made as of this 24th day of September 2018 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Pledgor”) and Cavalry Fund I LP, a Delaware limited partnership, in its capacity as agent (“Agent”) for the Purchasers ide
November 14, 2018	EX-10.8	Form of Senior Convertible Note issued September 24, 2018 EX-10.8 7 ex10-8.htm Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN
November 14, 2018	EX-10.11	Senior Convertible Note issued November 13, 2018 to Cavalry Fund I LP EX-10.11 10 ex10-11.htm Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURS
November 14, 2018	EX-10.7	Security Agreement dated September 24, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. EX-10.7 6 ex10-7.htm Execution Copy SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of September 24, 2018 between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (“OBMP”) and OncBioMune, Inc., a Louisiana corporation (the “Subsidiary”) (the Subsidiary, together with each other Person who becom
November 14, 2018	EX-10.4	Subsidiary Guaranty dated September 24, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. Execution Copy SUBSIDIARY GUARANTY This SUBSIDIARY GUARANTY (as amended, restated, supplemented, or otherwise modified and in effect from time to time, this “Guaranty”) is made as of this 24th day of September, 2018, jointly and severally, between OncBioMune Pharmaceuticals, Inc.
September 26, 2018	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2018 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction o
August 14, 2018	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIOM
July 31, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2018 (July 31, 2018) OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incor
July 31, 2018	EX-10.2	Form of Convertible Redeemable Note THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $150,000.
July 31, 2018	EX-10.1	Form of Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July , 2018, by and between OncBioMune Pharmaceuticals Inc.
July 2, 2018	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of i
July 2, 2018	EX-99.1	VITEL LABORATORIOS, S.A. DE C.V. FINANCIAL STATEMENTS December 31, 2016 VITEL LABORATORIOS, S.A. DE C.V. INDEX TO FINANCIAL STATEMENTS December 31, 2016 VITEL LABORATORIOS, S.A. DE C.V. FINANCIAL STATEMENTS December 31, 2016 VITEL LABORATORIOS, S.A. DE C.V. INDEX TO FINANCIAL STATEMENTS December 31, 2016 CONTENTS Report of Independent Registered Public Accounting Firm F-2 Financial Statements: Balance Sheet - As of December 31, 2016 F-3 Statement of Operations and Comprehensive Loss - For the period from January 16, 2016 (inception) to December 31
July 2, 2018	EX-99.2	ONCBIOMUNE PHARMACEUTICALS, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION ONCBIOMUNE PHARMACEUTICALS, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined balance sheet has been derived from the audited consolidated balance sheet of OncBiomune Pharmaceuticals, Inc. (the “Company”, “ONC”, or “we”) at December 31, 2016 as reflected in the Company’s Form 10-K for the period ended December 31, 2016 as filed with
June 19, 2018	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIO
May 31, 2018	EX-10.51	Securities Purchase Agreement dated March 13, 2018 between OncBioMune Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 13, 2018, between OncBioMune Pharmaceuticals, Inc.
May 31, 2018	EX-10.54	Security Agreement dated March 13, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of March 13, 2018 between OncBioMune Pharmaceuticals, Inc.
May 31, 2018	EX-10.50	Subsidiary Guaranty dated January 29, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. Execution Copy SUBSIDIARY GUARANTY This SUBSIDIARY GUARANTY (as amended, restated, supplemented, or otherwise modified and in effect from time to time, this “Guaranty”) is made as of this 29thday of January, 2018, jointly and severally, between OncBioMune Pharmaceuticals, Inc.
May 31, 2018	EX-10.49	Pledge Agreement dated January 29, 2018 between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP Execution Copy PLEDGE AGREEMENT THIS PLEDGE AGREEMENT made as of this 29th day of January, 2018 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), by OncBioMune Pharmaceuticals, Inc.
May 31, 2018	10-K	OBMP / OncBioMune Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52218 OncBioMun
May 31, 2018	EX-10.47	Form of Common Stock Purchase Warrant issued January 26, 2018 Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
May 31, 2018	EX-10.55	Pledge Agreement dated March 13, 2018 between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP EX-10.55 12 ex10-55.htm PLEDGE AGREEMENT THIS PLEDGE AGREEMENT made as of this 13th day of March, 2018 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Pledgor”) and Cavalry Fund I LP, a Delaware limited partnership, in its capacity as agent (subject to Section 1A, below) (“Agent”) for th
May 31, 2018	EX-10.56	Subsidiary Guaranty dated March 13, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. SUBSIDIARY GUARANTY This SUBSIDIARY GUARANTY (as amended, restated, supplemented, or otherwise modified and in effect from time to time, this “Guaranty”) is made as of this 13th day of March, 2018, jointly and severally, between OncBioMune Pharmaceuticals, Inc.
May 31, 2018	EX-10.45	Form of Securities Purchase Agreement dated January 29, 2018 between OncBioMune Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2018, between OncBioMune Pharmaceuticals, Inc.
May 31, 2018	EX-21.1	Subsidiaries of Registrant EXHIBIT 21.1 List of Subsidiaries Name of Subsidiaries Jurisdiction OncBioMune, Inc. Louisiana Vitel Laboratorios, S.A. de C.V. Mexico Oncbiomune México, S.A. De C.V. Mexico
May 31, 2018	EX-10.53	Form of Common Stock Purchase Warrant issued March 13, 2018 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM
May 31, 2018	EX-10.52	Form of Note issued March 13, 2018 (incorporated by reference to Exhibit 10.52 to registrant’s current report on Form 10-K filed with the SEC on May 31, 2018). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE
May 31, 2018	EX-10.46	Form of Note issued January 29, 2018 (incorporated by reference to Exhibit 10.46 to registrant’s current report on Form 10-K filed with the SEC on May 31, 2018). EX-10.46 3 ex10-46.htm Execution Copy NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
May 31, 2018	EX-10.48	Security Agreement dated January 29, 2018 between OncBioMune Pharmaceuticals, Inc. and OncBioMune, Inc. Execution Copy SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of January 29, 2018 between OncBioMune Pharmaceuticals, Inc.
May 16, 2018	NT 10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [
May 16, 2018	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2018 (March 11, 2018) OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incor
May 15, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2018 (March 19, 2018) OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incor
April 2, 2018	NT 10-K	OBMP / OncBioMune Pharmaceuticals, Inc. NT 10-K NT 10-K 1 nt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transitio
March 14, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2018 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Comm
January 30, 2018	8-K	OBMP / OncBioMune Pharmaceuticals, Inc. (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2018 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Co
December 29, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction (Commission (IRS Emp
December 29, 2017	EX-99.1	Resignation of Manuel Cosme Odabachian dated December 22, 2017.
November 20, 2017	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ON
November 14, 2017	NT 10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATEFILING CUSIP NUMBER 68235A 101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended September 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repor
September 14, 2017	10-Q	OBMP / OncBioMune Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIOM
August 14, 2017	NT 10-Q	OncBioMune Pharmaceuticals 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATEFILING CUSIP NUMBER 68235A 101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended June 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on
July 26, 2017	8-K	OncBioMune Pharmaceuticals (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction (Commission (IRS Employe
June 6, 2017	8-K	OncBioMune Pharmaceuticals (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction (Commission (IRS Employer
June 6, 2017	EX-10.7	Forbearance Agreement dated May 23, 2017 by and among OncBioMune Pharmaceuticals, Inc., Cavalry Fund I LP, Lincoln Park Capital Fund, LLC and Puritan Partners LLC Exhibit 10.7 Forbearance Agreement Forbearance Agreement, dated as of May 23, 2017, by and among the Cavalry Fund I LP, Lincoln Park Capital Fund, LLC, Puritan Partners LLC (individually, a ?Holder? and collectively the ?Holders?) and OncBioMune Pharmacueticals, Inc. (the ?Company?). Capitalized terms used herein shall have the meanings assigned to such terms in the 10% Senior Convertible Notes in
May 22, 2017	10-Q	OncBioMune Pharmaceuticals (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-52218 ONCBIO
May 16, 2017	424B3	1,375,679 Shares OncBioMune Pharmaceuticals, Inc. Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-208129 1,375,679 Shares OncBioMune Pharmaceuticals, Inc. Common Stock This prospectus relates to the offer and sale of up to 1,375,679 shares of common stock, par value $0.0001, of OncBioMune Pharmaceuticals, Inc., a Nevada corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the selling stockholder. The shares of commo
May 15, 2017	NT 10-Q	OncBioMune Pharmaceuticals 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A 101 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended March 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o
May 12, 2017	POS AM	As filed with the Securities and Exchange Commission May __ , 2017 As filed with the Securities and Exchange Commission May , 2017 Registration Statement No.
May 12, 2017	CORRESP	OncBioMune Pharmaceuticals ESP legal & compliance, llc laura aNTHONy, esquire LAZARUS ROTHSTEIN, ESQUIRE CHAD FRIEND, ESQUIRE, LLM JOHN CACOMANOLIS, ESQUIRE MARC S.
May 1, 2017	POS AM	As filed with the Securities and Exchange Commission April 28, 2017 As filed with the Securities and Exchange Commission April 28, 2017 Registration Statement No.
April 21, 2017	8-K	OncBioMune Pharmaceuticals (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2017 OncBioMune Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52218 20-2590810 (State or other jurisdiction of incorporation) (Comm
April 21, 2017	EX-10.1	Form of Non-Qualified Stock Option Agreement for Directors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 21, 2017). EX-10.1 2 ex10-1.htm Exhibit 10.1 NON-QUALIFIED STOCK OPTION AGREEMENT FOR DIRECTORS Name of Optionee: [] No. of Option Shares: [] Option Exercise Price per Share: $[] Grant Date: [] Expiration Date: Ten years after the Grant Date OncBioMune Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date
April 17, 2017	10-K	OncBioMune Pharmaceuticals (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-52218 OncBioMun
April 17, 2017	EX-21.1	OncBioMune Pharmaceuticals, Inc. Subsidiaries of the Registrant Exhibit 21.1 OncBioMune Pharmaceuticals, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation OncBioMune, Inc. Louisiana Oncbiomune México, S.A. De C.V. Mexico Vitel Laboratorios, S.A. de C.V. Mexico
April 3, 2017	NT 10-K/A	OncBioMune Pharmaceuticals 0-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-52218 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235A 101 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repor

THER / Theralink Technologies, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)